Science's 2024 Breakthrough of the Year — and Nobody Heard About It

Every December, Science — one of the most prestigious scientific journals in the world — names its Breakthrough of the Year. Past winners include CRISPR gene editing, the Higgs boson discovery, and the first image of a black hole.

In 2024, they named lenacapavir: a twice-yearly injectable drug that prevents HIV with near-perfect effectiveness.

How many people do you know who heard about this?

What Made It the Breakthrough of the Year

Science described lenacapavir as "a pivotal step toward diminishing HIV/AIDS as a global health crisis." The editorial wasn't using hyperbole. The trial results were genuinely unprecedented.

In the PURPOSE 1 trial — 5,300 cisgender women in South Africa and Uganda — not a single participant who received lenacapavir contracted HIV. Zero infections. 100% efficacy. When those results were announced at the AIDS 2024 conference in Munich, the room erupted.

The PURPOSE 2 trial — involving 3,200 cisgender men, transgender men, transgender women, and gender non-binary individuals across seven countries — showed 96% efficacy. Combined across all populations, it delivered what no PrEP option had before: near-perfect protection with the lowest possible patient burden.

Two injections per year. That's it.

The Science Behind It

Lenacapavir works differently from every other HIV medication. It's the first capsid inhibitor — a drug that targets the protein shell (capsid) surrounding HIV's genetic material. By rigidifying this protein, lenacapavir prevents the virus from assembling properly, entering cell nuclei, and replicating.

The breakthrough wasn't just pharmacological. It sprang from decades of basic science research into HIV's capsid structure — work led by researchers like Wesley Sundquist at the University of Utah, whose team discovered how the capsid is built and identified it as a drug target. Gilead Sciences developed lenacapavir as a direct result of that structural understanding.

Because lenacapavir binds so tightly and is released so slowly from the subcutaneous injection site, protective drug levels are maintained for six full months. No daily pills. No bimonthly clinic visits. Just two shots a year.

Why You Haven't Heard About This

There's no polite way to say this: the media largely ignored one of the most significant medical advances of the decade. HIV doesn't generate clicks the way it used to. The communities most affected — Black and Latino men who have sex with men, transgender women, people in the Global South — are among the least represented in mainstream media coverage.

The science world noticed. The FDA noticed (approval came June 18, 2025). The WHO noticed (prequalification in October 2025). But the public conversation never caught up.

This matters because awareness drives access. People can't ask for a drug they've never heard of. Providers can't prescribe what their patients don't know exists.

Can You Get It?

Yes. Yeztugo (the brand name for lenacapavir as PrEP) was FDA-approved on June 18, 2025. It's covered by:

• Private insurance at $0 under the ACA preventive services mandate (upheld by the Supreme Court in June 2025)
• Gilead Advancing Access for uninsured individuals at ≤500% FPL (~$60,300/year). Free. Phone: 1-800-226-2056.
• Medicaid in expansion states
• State PrEP DAPs where available

The same access pathways that cover daily oral PrEP cover Yeztugo. The only difference is the dosing schedule — and it's the best one we've ever had.

The Bigger Picture

Lenacapavir doesn't just matter for HIV. It's the first capsid inhibitor to succeed at this scale, and many viruses have their own capsid proteins. Science specifically noted this in their selection: the breakthrough raises the prospect of similar drugs targeting other viral diseases. The platform that produced lenacapavir could produce the next generation of antivirals.

In the nearer term, generic lenacapavir is expected by 2027 at roughly $40 per person per year in lower-income countries — down from thousands in the U.S. If that timeline holds, twice-yearly PrEP could become the tool that finally bends the global HIV epidemic toward zero.

This is the medical story of the decade. Tell someone about it.

Learn more: FreePrEP.org Injectable PrEP Guide →